Argenica Therapeutics Limited (ASX:AGN)

Market Cap	19.27M -51.6%
Revenue (ttm)	5.48M +70.7%
Net Income	-1.37M
EPS	-0.01
Shares Out	128.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Open	0.1500
Previous Close	0.1500
Day's Range	0.1500 - 0.1500
52-Week Range	0.0870 - 0.3450
Beta	0.78
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Argenica Therapeutics

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AGN

Financial Performance

In fiscal year 2026, Argenica Therapeutics's revenue was 5.48 million, an increase of 70.66% compared to the previous year's 3.21 million. Losses were -1.37 million, -80.96% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error